Sveits - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - gemfibrozilum - compresse rivestite con film - gemfibrozilum 450 mg, cellulosum microcristallinum, amylum pregelificatum, silica colloidalis anhydrica, polysorbatum 80, carboxymethylamylum natricum a corresp. natrium 0.34 mg, magnesii stearas, Überzug: hypromellosum, simethiconum, talcum, macrogolum 6000, e 171, pro compresso obducto. - disturbi del metabolismo dei grassi - synthetika

Sveits - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - gemfibrozilum - compresse rivestite con film - gemfibrozilum 900 mg, silica colloidalis anhydrica, silicii dioxidum praecipitatum, amylum pregelificatum, carboxymethylamylum natricum a corresp. natrium 0.68 mg, polysorbatum 80, magnesii stearas, Überzug: hypromellosum, simethiconum, talcum, macrogolum 6000, e 171, pro compresso obducto. - disturbi del metabolismo dei grassi - synthetika

Sveits - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

eli lilly (suisse) sa - selpercatinibum - capsule - capsule: selpercatinibum 40 mg, cellulosum microcristallinum, silica colloidalis anhydrica, matériel de la capsule: gelatina, e 171, e 172 (nigrum), encre: lacca, propylenglycolum, kalii hydroxidum, e 172 (nigrum), pro capsula. - ret-fusionspositives nicht-kleinzelliges lungenkarzinom (nsclc), ; ret-fusionspositives schilddrüsenkarzinom,; ret-mutantes medulläres schilddrüsenkarzinom - synthetika

Sveits - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

eli lilly (suisse) sa - selpercatinibum - capsule - capsule: selpercatinibum 80 mg, cellulosum microcristallinum, silica colloidalis anhydrica, matériel de la capsule: gelatina, e 171, e 133, encre: lacca, propylenglycolum, kalii hydroxidum, e 172 (nigrum), pro capsula. - ret-fusionspositives nicht-kleinzelliges lungenkarzinom (nsclc), ; ret-fusionspositives schilddrüsenkarzinom,; ret-mutantes medulläres schilddrüsenkarzinom - synthetika

Den europeiske union - italiensk - EMA (European Medicines Agency)

eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - agenti antineoplastici - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment.

Den europeiske union - italiensk - EMA (European Medicines Agency)

eli lilly nederland b.v. - pirtobrutinib - linfoma, cellule del mantello - inibitori della proteina chinasi - treatment of mantle cell lymphoma (mcl).

Italia - italiensk - Ministero della Salute

o.m.s. spa officine meccaniche specializzate - riuniti dentistici

Italia - italiensk - Ministero della Salute

gambro dasco s.p.a. - concentrati dialitici acidi non sterili

Italia - italiensk - Ministero della Salute

gambro dasco s.p.a. - concentrati dialitici acidi non sterili

Italia - italiensk - Ministero della Salute

gambro dasco s.p.a. - concentrati dialitici acidi non sterili